BEIJING, China and BRIDGEWATER, NJ, USA I June 21, 2025 I Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced that the ...

BASEL, Switzerland I June 23, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, ...

PLAINSBORO, NJ, USA I June 22, 2025 I Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial ...

CAMBRIDGE, MA, USA; ROTTERDAM, The Netherlands and SHANGHAI, China I June 22, 2025 I Harbour BioMed (HKEX: 02142), a global biopharmaceutical company ...

Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – ...

Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx – ...

AMSTERDAM, The Netherlands I June 20, 2025 I argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

GRAND RAPIDS, MI, USA I June 20, 2025 I Cirius Therapeutics, Inc., a developer of innovative therapies for patients suffering from diseases caused by ...

SAN DIEGO, CA, USA I June 20, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

With unmatched executional momentum and differentiated programs, Candid Therapeutics is defining a new future in immunology through its commitment to TCEs in autoimmune diseases. Additional trial ...

HONG KONG, China I June 20, 2025 I Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening ...

Company positioned to initiate multiple Phase 1 clinical trials in 2025 for ART-101 and additional novel radiopharmaceutical assets – ...